Viatris Inc.

Company Overview

Viatris Inc., headquartered in Pittsburgh, Pennsylvania, is a global pharmaceutical company formed in November 2020 by merging Mylan N.V. and Pfizer Inc.’s Upjohn division. The company focuses on providing access to affordable, high-quality medicines worldwide, operating in numerous countries with a diverse portfolio of generic drugs and biosimilars. Viatris Inc. is committed to improving global healthcare access and empowering individuals to lead healthier lives.

The executive team leads the company’s efforts, and it invests in R&D to advance its product pipeline. Viatris Inc. engages in various corporate social responsibility initiatives as a pharmaceutical entity, including sustainability and community engagement. Not all the products listed have been approved for use in all countries.

Financial Highlights (FY 2023)

Company's Business Segments

• Brands : Lipitor, Norvasc, Caduet, Inspra, Nitrostat, Revatio, Dilatin, Lyrica, Neurontin, Relpax
• Generics : Wixela, Inhub, ADVAIR DISKUS, Glatiramer acetate injection, Copaxone